93+ Active Mesothelioma Clinical Trials: Your 2026 Eligibility and Enrollment Guide

What Are the Key Facts About Mesothelioma Clinical Trial Eligibility?

• More than 93 mesothelioma clinical trials are actively recruiting patients worldwide as of April 2026, with 52 open to patients in the United States [1].
• The CheckMate 743 five-year update published in February 2026 demonstrated 14% five-year overall survival with nivolumab plus ipilimumab versus 6% with chemotherapy alone (HR 0.74), establishing the long-term durability of immunotherapy for pleural mesothelioma [2].
• Most trials require a confirmed tissue biopsy diagnosis, ECOG performance status of 0-2, adequate organ function, and age 18 or older [9][10].
• Biomarker-specific trials now require molecular testing: BAP1 loss for EZH2 inhibitor trials, MTAP deletion for PRMT5 inhibitors like MRTX1719, and mesothelin expression for CAR-T cell therapy [16].
• The eVOLVE-Meso trial (NCT06097728) is the largest actively enrolling Phase III study, targeting 825 patients globally to test volrustomig, a bispecific antibody targeting both PD-1 and CTLA-4 [3].
• Memorial Sloan Kettering's Phase I CAR-T trial achieved a 72% objective response rate using intrapleural delivery of mesothelin-targeted CAR-T cells combined with pembrolizumab [5].
• The UV1 telomerase vaccine received FDA Fast Track designation in February 2024, with NIPU Phase II data showing 31% objective response rate versus 16% in the control arm [6][7].
• Under the Affordable Care Act, health insurers are required to cover routine patient care costs during clinical trial participation [8].
• Enrollment from screening to first dose typically takes 2-6 weeks, depending on whether biomarker testing is needed [14].
• SEER data shows the 5-year survival rate for pleural mesothelioma at all stages is approximately 15%, rising to 23% for localized disease detected early [11].
• Five CAR-T cell therapy trials are currently open for mesothelioma, each requiring confirmed mesothelin expression on tumor tissue [5][16].
• The HIT-Meso trial (NCT05655078) is enrolling 148 patients in the United Kingdom for Phase III proton beam therapy, representing a non-drug option for eligible patients [4].

Who Qualifies for a Mesothelioma Clinical Trial in 2026?

Clinical trial eligibility is not a single yes-or-no determination. Each of the 93+ actively recruiting mesothelioma trials has its own inclusion and exclusion criteria, meaning a patient who does not qualify for one study may be an ideal candidate for another [15]. That said, nearly all mesothelioma trials share a set of baseline requirements that every prospective participant must meet.

"The single most important thing I tell families is that eligibility is not about whether you are 'sick enough' or 'healthy enough' for a trial. It is about matching your specific diagnosis, your functional status, and your molecular profile to the right study. That match exists for far more patients than most people realize."

— David Foster, Director of Client Services, Danziger & De Llano

The four universal eligibility pillars are:

1. Confirmed Histological Diagnosis. Every mesothelioma clinical trial requires a tissue biopsy confirming the diagnosis. Cytology alone (fluid analysis without tissue) is insufficient for most trials. Your pathology report must specify the histological subtype: epithelioid, sarcomatoid, or biphasic [10]. Some trials restrict enrollment to specific subtypes. For example, certain immunotherapy combinations have shown the most dramatic benefit in non-epithelioid (sarcomatoid and biphasic) pleural mesothelioma, where the CheckMate 743 five-year data showed 12% versus just 1% survival with chemotherapy [2].

2. ECOG Performance Status of 0-2. The Eastern Cooperative Oncology Group (ECOG) scale measures your ability to carry out daily activities on a 0-5 scale [9]. Nearly all mesothelioma trials require an ECOG score between 0 and 2:

• ECOG 0: Fully active, no restrictions on physical activity
• ECOG 1: Restricted in strenuous activity but ambulatory and able to carry out light work (office work, light housework)
• ECOG 2: Ambulatory and capable of all self-care, up and about more than 50% of waking hours, but unable to carry out any work activities

Patients with ECOG 3 or higher (in bed more than 50% of the day) are generally excluded because experimental treatments carry additional risks when functional capacity is significantly limited. Your oncologist assesses your ECOG score during screening.

3. Adequate Organ Function. Blood tests during screening must confirm that your kidneys, liver, and bone marrow are functioning well enough to safely process experimental treatments. Standard thresholds include adequate creatinine clearance (kidney), bilirubin and transaminase levels within acceptable ranges (liver), and sufficient absolute neutrophil count, platelet count, and hemoglobin (bone marrow) [10]. These values vary by trial but are designed to protect you from excessive toxicity.

4. Age 18 or Older. Mesothelioma is overwhelmingly an adult disease with a median age at diagnosis of 72, and all currently recruiting trials require participants to be at least 18 years old [11].

What Biomarker Tests Determine Which Trials You Can Access?

The era of one-size-fits-all mesothelioma treatment is ending. An increasing number of clinical trials in 2026 require specific biomarker results before you can enroll. Understanding which tests to request and what the results mean can open doors to targeted therapies that were not available even two years ago.

"I always recommend patients ask their oncologist for comprehensive biomarker testing at diagnosis. Even if the first treatment plan does not depend on it, those results will be essential if a clinical trial becomes an option later. Getting tested after progression costs time you may not have."

— David Foster, Director of Client Services, Danziger & De Llano

BAP1 Loss (for EZH2 Inhibitor Trials). BAP1 is a tumor suppressor gene lost in approximately 60% of pleural mesothelioma cases. Trials testing EZH2 inhibitors specifically target tumors that have lost BAP1 function, because EZH2 activity becomes essential for tumor growth in these cells. BAP1 status is determined through immunohistochemistry (IHC) on your biopsy tissue, a test that most major pathology labs can perform [10]. If you have BAP1 loss, you may qualify for trials exploring this targeted vulnerability.

MTAP Deletion (for PRMT5 Inhibitor Trials). MTAP (methylthioadenosine phosphorylase) is a gene located near the commonly deleted CDKN2A locus on chromosome 9p21. When MTAP is deleted, tumor cells become vulnerable to PRMT5 inhibition. The MRTX1719 trial specifically requires confirmed MTAP deletion, typically determined through fluorescence in situ hybridization (FISH) testing. MTAP deletion occurs in an estimated 40-50% of pleural mesothelioma cases, making this a significant patient population [10].

Mesothelin Expression (for CAR-T Cell Therapy Trials). CAR-T cell therapy for mesothelioma works by engineering a patient's own T cells to recognize and attack mesothelin, a protein expressed on the surface of mesothelioma tumor cells. Five CAR-T trials are currently open, and all require confirmed mesothelin expression on tumor tissue, typically measured by IHC [5][16]. The landmark Memorial Sloan Kettering Phase I trial using intrapleural delivery of mesothelin-targeted CAR-T cells combined with pembrolizumab achieved a 72% objective response rate, generating significant interest in this approach [5].

PD-L1 Expression (informational, not always required). While PD-L1 expression levels are routinely tested, most current mesothelioma clinical trials using immune checkpoint inhibitors do not require a specific PD-L1 threshold for enrollment. The CheckMate 743 trial demonstrated benefit regardless of PD-L1 status [2][12]. However, some newer combination studies may stratify patients by PD-L1 levels, so having this result on file is valuable.

What Are the Specific Eligibility Criteria for the Most Promising 2026 Trials?

Each trial has unique criteria beyond the universal requirements. Here is what you need to know about the most impactful studies currently enrolling:

eVOLVE-Meso (NCT06097728) - First-Line Bispecific Immunotherapy. This Phase III trial is the largest actively enrolling mesothelioma study, targeting 825 patients worldwide [3]. It tests volrustomig, a bispecific antibody that simultaneously blocks PD-1 and CTLA-4, combined with carboplatin and pemetrexed. Key eligibility requirements include: unresectable malignant pleural mesothelioma confirmed by histology, no prior systemic anticancer therapy for mesothelioma (first-line patients only), ECOG 0-1 (stricter than many trials), and adequate organ function. Patients who have received prior immunotherapy are excluded.

CAR-T Cell Therapy Trials (5 Open Studies). These early-phase trials are exploring different approaches to CAR-T delivery in mesothelioma. The MSK intrapleural CAR-T trial requires: confirmed mesothelin expression by IHC, pleural mesothelioma specifically (peritoneal patients are eligible in some but not all CAR-T trials), ECOG 0-1, and at least one prior line of platinum-based chemotherapy [5]. Patients with active autoimmune disease or those who have received prior CAR-T therapy are typically excluded.

UV1 Telomerase Vaccine Trials. Building on the NIPU Phase II results showing 31% objective response rate versus 16% in the control arm, UV1 vaccine trials require: confirmed unresectable pleural mesothelioma, prior treatment with at least one line of platinum-based chemotherapy, ECOG 0-2, and no active autoimmune conditions requiring systemic immunosuppression [6][7]. The vaccine received FDA Fast Track designation in February 2024, accelerating its path toward potential approval.

HIT-Meso Proton Beam Therapy (NCT05655078). This UK-based Phase III trial offers a non-drug option for eligible patients, enrolling 148 patients to evaluate proton beam therapy for pleural mesothelioma [4]. Eligibility includes: confirmed malignant pleural mesothelioma, disease amenable to radical radiation (typically earlier-stage or post-surgical), ECOG 0-1, and ability to travel to a participating UK proton therapy center. This trial is particularly relevant for patients seeking radiation-based approaches.

How Does Your Treatment History Affect Which Trials You Can Join?

Your prior treatment experience is one of the most important factors in determining trial eligibility. Trials are categorized by "line of therapy," and each line opens different options:

Treatment-Naive (No Prior Systemic Therapy). If you have not yet received chemotherapy, immunotherapy, or other systemic treatment for mesothelioma, you qualify for first-line trials. The largest option is eVOLVE-Meso (NCT06097728), which tests volrustomig plus chemotherapy against standard chemotherapy alone [3]. First-line trials typically offer access to the most promising new combinations before any standard treatment begins.

After First-Line Treatment (Second-Line and Beyond). Patients who have progressed after platinum-based chemotherapy gain access to a different set of trials. The UV1 vaccine trials, most CAR-T cell studies, and several targeted therapy trials specifically require at least one prior line of treatment [5][6]. This requirement exists because these therapies are being evaluated as alternatives after standard treatment has stopped working.

After Immunotherapy (Post-Checkpoint Inhibitor). A growing category of trials targets patients whose disease has progressed after receiving immune checkpoint inhibitors like nivolumab plus ipilimumab. These trials explore mechanisms to overcome immunotherapy resistance, including bispecific antibodies, cellular therapies, and novel combinations. If you received immunotherapy as part of your treatment, trials in this space may be relevant.

"Every treatment you receive does not close doors. It opens different ones. A patient who has had chemotherapy and then immunotherapy actually qualifies for a subset of trials that a newly diagnosed patient cannot access. We map each patient's treatment history to the full landscape of open studies."

— David Foster, Director of Client Services, Danziger & De Llano

What Are the Most Common Reasons Patients Are Excluded from Mesothelioma Trials?

Understanding exclusion criteria is just as important as knowing the inclusion requirements. The most frequent reasons mesothelioma patients are screened out of clinical trials include:

ECOG Performance Status Too Low. If your ECOG score is 3 or higher, meaning you are confined to bed or a chair more than 50% of waking hours, most trials will not enroll you. This is the single most common barrier [9]. Working with your medical team to manage symptoms and improve functional status may move you from ECOG 3 to ECOG 2, reopening eligibility for many studies.

Inadequate Organ Function. Kidney impairment, elevated liver enzymes, or low blood counts can disqualify patients from trials that use agents processed by these organs. Some of these values can improve with supportive care, hydration, or adjusting current medications. Ask your oncologist whether any borderline lab values might be correctable before assuming disqualification [10].

Active Autoimmune Disease. Immunotherapy trials, which represent the majority of mesothelioma studies in 2026, typically exclude patients with active autoimmune conditions such as rheumatoid arthritis, lupus, or inflammatory bowel disease that require systemic immunosuppression. The concern is that checkpoint inhibitors may exacerbate autoimmune symptoms. Patients with well-controlled autoimmune conditions not requiring immunosuppressive medication may still qualify for select trials.

Brain Metastases. Active, untreated brain metastases are an exclusion criterion for nearly all mesothelioma trials. However, patients with previously treated and stable brain metastases (typically stable for 4 or more weeks) may qualify for some studies. Brain metastases are uncommon in mesothelioma but should be evaluated if neurological symptoms are present.

Prior Therapy Conflicts. Receiving a specific treatment within a defined washout period before the trial begins can cause exclusion. For example, some trials require that you have not received chemotherapy within 3-4 weeks or surgery within 4-6 weeks of enrollment. These washout periods allow your body to recover and ensure that the experimental treatment's effects can be measured cleanly [15].

What Steps Do You Need to Take to Enroll in a Mesothelioma Clinical Trial?

The enrollment process involves several sequential steps. Knowing what to expect helps you prepare documents, coordinate with your medical team, and minimize delays.

Step 1: Gather Your Medical Records (3-7 Days). Before contacting any trial site, assemble your complete medical records including: pathology report with histological subtype, all imaging (CT, PET, MRI), prior treatment records with dates and responses, recent blood work, and any biomarker testing results. Having these ready accelerates the prescreening process significantly [14].

Step 2: Identify Matching Trials. Search ClinicalTrials.gov using the condition "mesothelioma" filtered by "Recruiting" status and your geographic location [1]. The NCI's Cancer Information Service (1-800-4-CANCER) provides free personalized trial matching. Your oncologist, especially if at a mesothelioma treatment center, can also identify trials that match your profile.

Step 3: Contact the Trial Site. Each trial listing on ClinicalTrials.gov includes contact information for the research coordinator at each participating site. Call or email to express interest and ask about current enrollment status. Some trials that are technically "recruiting" may have reached capacity at specific sites while remaining open at others.

Step 4: Prescreening Review. The trial team reviews your medical records to determine preliminary eligibility before scheduling an in-person visit. This remote review can save you an unnecessary trip if a clear exclusion criterion is identified early. Be prepared to share records electronically or by fax.

Step 5: Screening Visit (1-2 Days). If prescreening is positive, you will be scheduled for an on-site screening visit. This typically includes a physical examination, blood draws for organ function tests, updated imaging if needed, and a review of the informed consent document. Some trials require a new biopsy for biomarker testing at this stage [14].

Step 6: Biomarker Testing (5-14 Days for Results). If the trial requires specific biomarker results (BAP1, MTAP, mesothelin, PD-L1), tissue from your biopsy is sent for testing. Results can take 1-2 weeks. If you already have recent biomarker results from a CLIA-certified laboratory, the trial team may accept those, saving significant time.

Step 7: Eligibility Confirmation and Enrollment (3-7 Days). The trial's principal investigator reviews all screening data and confirms your eligibility. You sign the informed consent document, which details the treatment protocol, potential risks and benefits, your rights as a participant, and the process for withdrawing if you choose. Your first treatment visit is then scheduled [15].

"The biggest mistake I see families make is waiting until all standard options are exhausted before exploring trials. By then, performance status may have declined, organ function may be compromised, and fewer trials are available. The best time to research trials is immediately after diagnosis, even if you ultimately choose standard treatment first."

— David Foster, Director of Client Services, Danziger & De Llano

What Will Insurance Cover During a Mesothelioma Clinical Trial?

Financial concerns should not prevent you from exploring clinical trial participation. Federal law and insurance regulations provide significant protections for trial participants.

The Affordable Care Act (ACA) Requirement. Section 2709 of the ACA prohibits health insurance plans from dropping coverage or increasing premiums because you participate in a clinical trial. More importantly, insurers are required to cover routine patient care costs during trial participation [8]. Routine costs include standard-of-care treatments, doctor visits, hospitalizations, lab tests, and imaging that you would receive regardless of whether you were in a trial.

What the Trial Sponsor Covers. The pharmaceutical company, the National Cancer Institute, or the academic institution sponsoring the trial covers the cost of the investigational drug or treatment itself. You will not be billed for the experimental therapy. Many sponsors also cover trial-specific procedures such as additional biopsies or specialized imaging required by the study protocol but not part of standard care [15].

Medicare Coverage. Medicare covers routine costs for beneficiaries participating in qualifying clinical trials under the Clinical Trial Policy, including trials funded by the NIH, FDA, Department of Defense, VA, or conducted at NCI-designated cancer centers [13]. Given that the median age of pleural mesothelioma diagnosis is 72, Medicare coverage is relevant for the majority of patients.

Travel and Lodging Assistance. Some trials offer stipends for travel and lodging, particularly multi-site trials where patients may need to travel to participating centers. Organizations such as the American Cancer Society and CancerCare offer grants specifically for clinical trial travel expenses. Ask the research coordinator about available support during your prescreening call.

How Do You Find the Right Trial for Your Specific Situation?

With 93+ trials recruiting, narrowing down the right match requires a systematic approach. The most effective strategy combines digital resources with expert guidance.

ClinicalTrials.gov. The primary database for all registered clinical trials in the United States and internationally. Search for "mesothelioma" and filter by "Recruiting" status, your state or country, intervention type (drug, biological, radiation, device), and phase (Phase I, II, or III) [1]. Each listing includes full eligibility criteria, participating locations, and contact information.

NCI Cancer Information Service. The NCI offers a free trial matching service at 1-800-4-CANCER. Specialists review your diagnosis details and match them against all NCI-supported trials, providing a personalized list of options [14]. This is particularly valuable if navigating ClinicalTrials.gov feels overwhelming.

Mesothelioma Treatment Centers. Institutions such as Memorial Sloan Kettering, MD Anderson, Brigham and Women's, the University of Chicago, and Moffitt Cancer Center run multiple mesothelioma trials simultaneously and can evaluate you for all of them in a single visit [10]. If you are not currently treated at a major treatment center, consider requesting a consultation specifically to discuss trial options.

Your Advocate Team. Patient advocates who specialize in mesothelioma can help navigate the trial landscape, coordinate records transfers, and connect you with research coordinators. At Danziger and De Llano, we help clients understand their clinical trial options as part of our comprehensive case support. For additional resources, visit our mesothelioma clinical trials guide, learn about legal options for mesothelioma patients, or explore our mesothelioma lawyer center. Call 855-699-5441 or take our free assessment to get started.

What Should You Ask Before Enrolling in Any Mesothelioma Clinical Trial?

Before signing an informed consent document, ensure you have clear answers to these questions from the research team:

• What is the purpose of this study and what phase is it in?
• Is there a placebo arm, and if so, what is my chance of receiving the active treatment versus placebo?
• What are the known side effects of the investigational treatment based on earlier trial phases?
• How often will I need to visit the trial site, and what does each visit involve?
• Will I need additional biopsies or procedures beyond standard care?
• What happens if the treatment does not work or if I experience severe side effects?
• Can I continue receiving the treatment after the trial ends if it is helping?
• Are there any costs I will be responsible for that are not covered by insurance or the sponsor?
• Will participation in this trial affect my ability to enroll in a different trial later?

These questions are not signs of hesitation. They are signs of an informed participant, and every reputable trial team expects and welcomes them [15].

What Is the Current Landscape of Mesothelioma Clinical Trials in 2026?

The mesothelioma clinical trial landscape in 2026 is the most active and diverse it has ever been. The 93+ recruiting trials span multiple therapeutic categories, giving patients more options than at any previous point:

Immunotherapy Combinations. Building on the CheckMate 743 success that established nivolumab plus ipilimumab as a standard first-line treatment for pleural mesothelioma [2][12], new combination approaches are being tested. The eVOLVE-Meso trial (NCT06097728) represents the next generation, using a bispecific antibody (volrustomig) that targets both PD-1 and CTLA-4 in a single molecule combined with standard chemotherapy [3]. Multiple trials are also exploring combinations with novel agents after initial immunotherapy.

CAR-T Cell Therapy. Five open CAR-T trials are targeting mesothelin on mesothelioma cells, with the MSK intrapleural approach producing the most striking early results at a 72% objective response rate [5]. These trials represent a fundamentally different approach where your own immune cells are engineered to recognize and destroy tumor cells. Eligibility requires mesothelin expression confirmed by IHC [16].

Cancer Vaccines. The UV1 telomerase vaccine is the most advanced, with FDA Fast Track designation and Phase II data showing nearly double the response rate versus control (31% vs 16%) [6][7]. Vaccine approaches aim to train the immune system to recognize telomerase, a protein that mesothelioma cells depend on for survival.

Targeted Therapies. Biomarker-driven trials for BAP1 loss (EZH2 inhibitors) and MTAP deletion (PRMT5 inhibitors including MRTX1719) represent the push toward precision medicine in mesothelioma. These therapies exploit specific genetic vulnerabilities in individual tumors rather than applying a one-size-fits-all approach [10].

Proton Beam Therapy. The HIT-Meso trial (NCT05655078) is evaluating proton beam therapy in 148 patients, offering a non-drug option that may deliver radiation more precisely to the tumor while sparing surrounding healthy tissue [4].

"When I started working with mesothelioma patients 18 years ago, the conversation about clinical trials was short because the options were few. Today I spend more time helping patients choose between trials than convincing them trials exist. That shift represents real progress."

— David Foster, Director of Client Services, Danziger & De Llano

What Are the Most Common Questions About Mesothelioma Clinical Trial Eligibility?

What are the basic eligibility requirements for mesothelioma clinical trials?

Most mesothelioma clinical trials require a confirmed tissue biopsy diagnosis, age 18 or older, an ECOG performance status of 0-2 (meaning you can care for yourself and are up and about more than 50% of waking hours), and adequate organ function as measured by blood tests for kidney, liver, and bone marrow function [9][10]. Specific trials add requirements such as prior treatment history, histological subtype, and biomarker expression levels.

Do I need specific biomarker results to join a mesothelioma clinical trial?

Some trials require specific biomarker results while others do not. Targeted therapy trials require confirmed biomarker status: EZH2 inhibitor trials require BAP1 loss confirmed by immunohistochemistry, PRMT5 inhibitor trials like MRTX1719 require MTAP deletion confirmed by FISH testing, and CAR-T cell therapy trials require mesothelin expression on tumor cells [5][16]. Immunotherapy combination trials and vaccine trials generally accept patients regardless of biomarker status.

Will my insurance cover the costs of participating in a clinical trial?

Under the Affordable Care Act, health insurance plans are required to cover routine patient care costs during clinical trial participation, including standard doctor visits, lab work, and imaging [8]. The trial sponsor covers the cost of the investigational treatment itself. Medicare covers routine costs for beneficiaries in qualifying clinical trials under the Clinical Trial Policy [13]. Some trials also offer stipends for travel and lodging.

Can I join a clinical trial if I have already received chemotherapy?

Yes, many trials are specifically designed for patients who have already received one or more lines of chemotherapy. Second-line and later-line trials such as the UV1 vaccine trial and several CAR-T cell therapy trials require prior platinum-based chemotherapy [5][6]. However, some first-line trials like eVOLVE-Meso require that you have not yet received systemic treatment for mesothelioma [3]. Your treatment history determines which trials you qualify for, not whether you qualify at all.

How long does the clinical trial enrollment process take?

From initial screening to first treatment dose, mesothelioma clinical trial enrollment typically takes 2-6 weeks. The process includes obtaining medical records (3-7 days), screening visit with labs and imaging (1-2 days), biomarker testing if required (5-14 days), eligibility confirmation (3-7 days), and scheduling the first treatment visit [14][15]. Patients who already have recent imaging, pathology reports, and biomarker results can sometimes begin within 2 weeks.

What is an ECOG performance status and why does it matter for trial eligibility?

ECOG performance status is a 0-5 scale that measures how well you can carry out daily activities [9]. Most mesothelioma trials require ECOG 0-2: ECOG 0 means fully active, ECOG 1 means restricted in strenuous activity but able to do light work, and ECOG 2 means up and about more than 50% of waking hours and capable of all self-care. ECOG 3-4 patients are generally excluded because experimental treatments may pose greater risk when functional status is significantly impaired.

Are there mesothelioma clinical trials for peritoneal mesothelioma specifically?

Yes, though fewer in number. Some trials enroll both pleural and peritoneal mesothelioma patients, including the eVOLVE-Meso trial and several CAR-T cell therapy trials. A few studies focus specifically on peritoneal mesothelioma, particularly those involving heated intraperitoneal chemotherapy (HIPEC) combined with cytoreductive surgery. For a deeper understanding of your mesothelioma diagnosis and how your subtype affects trial eligibility, speak with a mesothelioma specialist. The NCI's Cancer Information Service at 1-800-4-CANCER can help identify trials accepting peritoneal mesothelioma patients specifically.

References

1. ClinicalTrials.gov Search Results: Mesothelioma Recruiting Studies. U.S. National Library of Medicine. clinicaltrials.gov
2. Scherpereel A, et al. Five-Year Outcomes With Nivolumab Plus Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743. J Clin Oncol. 2026;44(9):742-749. PubMed
3. eVOLVE-Meso: Volrustomig Plus Chemotherapy in Untreated Unresectable Malignant Pleural Mesothelioma. NCT06097728
4. HIT-Meso: Proton Beam Therapy in Malignant Pleural Mesothelioma. NCT05655078
5. Adusumilli PS, et al. A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease. Cancer Discov. 2021;11(11):2748-2763. PubMed
6. Haakensen VD, et al. NIPU: Nivolumab and Ipilimumab Combined with UV1 Telomerase Vaccine in Pleural Mesothelioma. Eur J Cancer. 2024;202:113973. PubMed
7. FDA Fast Track Designation: UV1 Cancer Vaccine for Mesothelioma. FDA.gov
8. Patient Protection and Affordable Care Act: Coverage of Clinical Trials (Section 2709). Congress.gov
9. NCI Dictionary: ECOG Performance Status. Cancer.gov
10. Malignant Mesothelioma Treatment (PDQ) - Health Professional Version. Cancer.gov
11. SEER Cancer Stat Facts: Mesothelioma. SEER
12. Baas P, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743). Lancet. 2021. PubMed
13. Medicare Coverage of Clinical Trials. Medicare.gov
14. Steps to Find a Clinical Trial. Cancer.gov
15. Learn About Clinical Studies. ClinicalTrials.gov
16. Hassan R, et al. Mesothelin Immunotherapy for Cancer: Ready for Prime Time? J Clin Oncol. 2016;34(34):4171-4179. PubMed